Dabuzalgron
产品说明书
 |
同义名 : | Ro 115-1240 |
| CAS号 : | 219311-44-1 | |
| 货号 : | A258735 | |
| 分子式 : | C12H16ClN3O3S | |
| 纯度 : | 97% | |
| 分子量 : | 317.79 | |
| MDL号 : | MFCD13195546 | |
| 存储条件： |
Pure form Sealed in dry, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Dabuzalgron, also known as Ro 115-1240, is an orally active and selective agonist of the α-1A adrenergic receptor used for the treatment of urinary incontinence. Dabuzalgron prevents Doxorubicin-induced cardiotoxicity by protecting mitochondrial function. After 15 minutes of treatment, Dabuzalgron increased ERK phosphorylation in a dose-dependent manner with an EC50 value of 4.8 μM. ERK1/2 activation contributes to the cardioprotective effects of Dabuzalgron. At a concentration of 10 μM for 4 hours, Dabuzalgron protects NRVMs from Doxorubicin-induced cell death. Activation of α1A-AR by Dabuzalgron attenuates the deleterious effects of Doxorubicin on the mitochondrial membrane potential and attenuates the activation of factors important for the apoptotic response resulting from mitochondrial damage[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.15mL 0.63mL 0.31mL |
15.73mL 3.15mL 1.57mL |
31.47mL 6.29mL 3.15mL |
